Company Analysis
Sign in

Fate Therapeutics, Inc. (FATE)

Nasdaq: FATE · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2008
Full chart Alerts Compare
Grade4.1
◀ Past 5.1● Present 4.5▶ Future 3.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

48 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Fate Therapeutics, Inc.’s names, not what it holds today.

Patents granted
48
47 utility, 1 design, 1976 to Dec 31, 2025
Granted in 2025
12
Against 4 in 2024 and 3 in 2023
Applications published
95
12 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology16
Pharmaceuticals14
Medical technology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Fate Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
84 published
FATE THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
48 granted
11 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 7, 202512,435,123Immunotherapies using enhanced iPSC derived effector cellsBiotechnologyFATE THERAPEUTICS, INC.
Sep 23, 202512,419,870Compositions and methods for immune cell modulation in adoptive immunotherapiesPharmaceuticalsFATE THERAPEUTICS, INC.
Sep 16, 202512,415,989Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsBiotechnologyFATE THERAPEUTICS, INC.
Sep 9, 202512,410,403Methods and compositions for inducing hematopoietic cell differentiationPharmaceuticalsFATE THERAPEUTICS, INC.
Aug 26, 202512,398,373Enhanced immune effector cells and use thereofBiotechnologyFATE THERAPEUTICS, INC.
Aug 12, 202512,385,012Methods and compositions for inducing hematopoietic cell differentiationBiotechnologyFATE THERAPEUTICS, INC.
Jul 8, 202512,351,831Platform for the induction and maintenance of ground state pluripotencyBiotechnologyFATE THERAPEUTICS, INC.
Apr 22, 202512,281,329Compositions and methods for immune cell modulation in adoptive immunotherapiesPharmaceuticalsFATE THERAPEUTICS, INC.
Apr 15, 202512,275,955Combining iPSC derived effector cell types for immunotherapy useBiotechnologyFATE THERAPEUTICS, INC.
Apr 1, 202512,264,322Minimal volume reprogramming of mononuclear cellsPharmaceuticalsFATE THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388646ENHANCING EFFECTOR CELL DURABILITY AND EFFICACY IN ADOPTIVE CELL THERAPIESBiotechnologyFate Therapeutics, Inc.
Nov 6, 20252025/0339532STEALTH STRATEGY ENGAGING IMMUNE RECOGNITION PATHWAYS FOR USE IN ALLOGENEIC CELL THERAPIESMedical technologyFate Therapeutics, Inc.
Oct 9, 20252025/0313802COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USEBiotechnologyFate Therapeutics, Inc.
Aug 21, 20252025/0263670CELLULAR REPROGRAMMING USING TEMPORAL AND TRANSIENT PLASMID VECTOR EXPRESSION SYSTEMBiotechnologyFate Therapeutics, Inc.
Jul 17, 20252025/0228943CELLS HAVING SOLID TUMOR TARGETING BACKBONE AND USE THEREOFBiotechnologyFate Therapeutics, Inc.
Jul 10, 20252025/0222029CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETINGMedical technologyFate Therapeutics, Inc.
Jul 3, 20252025/0215396COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIESPharmaceuticalsFate Therapeutics, Inc.
May 8, 20252025/0145966ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOFBiotechnologyFate Therapeutics, Inc.
Jan 30, 20252025/0032547EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORSBiotechnologyFate Therapeutics, Inc.
Jan 16, 20252025/0018034ENGINEERED EFFECTOR CELLS AND METHODS OF ENHANCING UBIQUITOUS TARGETING OF SOLID TUMORSMedical technologyFate Therapeutics, Inc.
What it applied for, 2024 to 2025: Biotechnology 14 · Medical technology 5 · Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton FATE · research, not advice